Loading
A phase 1 trial of IMC-002 run by ImmuneOncia Therapeutics Inc., completed.
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas is a phase 1 interventional study registered as NCT04306224 by ImmuneOncia Therapeutics Inc., with 12 participants enrolled, started 2020-06-05. Conditions recorded: Solid Tumor and Lymphoma. Interventions recorded: IMC-002.
Shares IMC-002, ImmuneOncia Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares ImmuneOncia Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares ImmuneOncia Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares ImmuneOncia Therapeutics and the tag pipeline.
Shares ImmuneOncia Therapeutics and the tag pipeline.
Shares ImmuneOncia Therapeutics and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/